Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14813255 | 0.84 | TAS1R3 (0.33) | — | |
| SCHEMBL585432 | 0.81 | POLB (0.33) | — | |
| SCHEMBL585431 | 0.81 | POLB (0.33) | — | |
| SCHEMBL7596283 | 0.78 | HDAC1 (0.32) | — | |
| SCHEMBL584055 | 0.78 | HDAC1 (0.37) | — | |
| SCHEMBL28223236 | 0.68 | — | — | |
| SCHEMBL5161425 | 0.68 | GLS2 (0.41) | CTSK | |
| SCHEMBL4654249 | 0.66 | CTSK (0.44) | CTSK | |
| SCHEMBL6943788 | 0.66 | ALDH1A1 (0.45) | — | |
| SCHEMBL3801260 | 0.64 | PRKCA (0.44) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765204-B2 | Carbonothioates as flavours and fragrances | GIVAUDAN S.A. (CH) | 2014-07-01 | — | — | US | claimed |
| EP-2417105-B1 | CARBONOTHIOATES AS FLAVOURS AND FRAGRANCES | GIVAUDAN SA (CH) | 2013-04-03 | — | — | EP | claimed |
| US-20120052178-A1 | Carbonothioates As Flavours and Fragrances | GIVAUDAN SA (CH) | 2012-03-01 | — | — | US | claimed |
| EP-2417105-A1 | CARBONOTHIOATES AS FLAVOURS AND FRAGRANCES | Givaudan SA (CH) | 2012-02-15 | — | — | EP | claimed |
| WO-2010115920-A1 | CARBONOTHIOATES AS FLAVOURS AND FRAGRANCES | GIVAUDAN SA (CH) | 2010-10-14 | — | — | WO | claimed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| US-8765204-B2 | Carbonothioates as flavours and fragrances | GIVAUDAN S.A. (CH) | 2014-07-01 | — | — | US | disclosed |
| EP-2417105-B1 | CARBONOTHIOATES AS FLAVOURS AND FRAGRANCES | GIVAUDAN SA (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120052178-A1 | Carbonothioates As Flavours and Fragrances | GIVAUDAN SA (CH) | 2012-03-01 | — | — | US | disclosed |
| EP-2417105-A1 | CARBONOTHIOATES AS FLAVOURS AND FRAGRANCES | Givaudan SA (CH) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115920-A1 | CARBONOTHIOATES AS FLAVOURS AND FRAGRANCES | GIVAUDAN SA (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052178-A1 | Carbonothioates As Flavours and Fragrances | PFAS, MGMT, RNGTT | CTSK 4584/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CTSK 3504/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | CTSK 3504/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CTSK 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.